Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

21 Jul 2026, 22:51 UTC · 2h ago

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Adma Biologics (ADMA) is currently assigned a Zacks Rank of #5 (Strong Sell). — A 'Strong Sell' rating from a quantitative ranking system typically signals a bearish outlook and potential price decline.
-0.70
2
The Zacks Consensus EPS estimate for Adma Biologics has shifted 2.03% downward over the past month. — Downward revisions in earnings expectations generally lead to lower stock valuations as growth prospects dim.
-0.40
3
Adma Biologics' upcoming quarterly EPS is projected at $0.16, a 6.67% increase year-over-year. — Projected growth in earnings is fundamentally positive, though the magnitude here is modest.
+0.20
4
Adma Biologics is trading at a Forward P/E ratio of 10.89, significantly lower than its industry average of 19.23. — A lower P/E relative to peers suggests the stock may be undervalued, though it can also reflect fundamental weaknesses.

6 related stories

Adma Biologics (ADMA) Sto… — ADMA -0.60 | NewsImpactScreener